Summary of the COVID-19 vaccine supply agreements for Europe (incl. the UK & Switzerland), the US, and Japan
The first human data of the most advanced COVID-19 vaccines have been disclosed over the past couple of months (see references in our tracker of the European “COVID” biotechs), but the first pre-orders have even been registered without having seen any data. The preliminary immunogenicity and safety data have been sufficiently promising to keep this[…]
The European listed biotech companies with COVID-19 programs: status & follow-up (updated 16/08/2020)
In the context of the COVID-19/SARS-Cov-2 pandemic, many biopharma companies throughout the world try to bring therapeutic options, on top of the topic of testing, which will not be focused on here. Some European listed companies have joined this international effort over the past weeks, and especially since the month of March. Vaccine development has[…]
European listed biotech companies: stock performance tracking after the coronavirus outbreak (updated)
The markets have been very volatile lately, and the main indices have known historical sessions in terns or performances on last Monday (09/03/2020), and even worse on last Thursday (12/03/2020, a real “Black Thursday” of the 21st century). That day, the European markets saw either their largest falls ever, either their worst performances since 19/10/1987[…]
2018 was a very bad year for the European biotech landscape, so the question was whether a rebound coud take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]
So far, we listed 39 abstracts from the European listed biotech companies or their partners for the ASH 2019 Annual meeting, excluding those relating to daratumumab (16 abstracts by Janssen/JNJ). Morphosys will present 7 abstracts and Oncopeptides 6. Cellectis and partners gather 4 presentations. Argenx will have 2 oral presentations, one for efgartigimod in ITP,[…]
Stock performances of the European listed biotech companies were positive at the end of 30/09/2019, on average. However, the median performance is -9.0%, leads to an easy conclusion: the average performance was driven by outliers on the gaining side. Unlike 2018, where overall, there was a common pattern downwards, 2019 data are heavily spread among[…]
It’s time to make a top view status of the deal activity for the 150+ European listed biotech companies in our universe. The data below include deals from all categories (R&D collaborations, Out-Licensing deals, Supply/Distribution deals, JV, IP licensing, Sales/Divestments), except the in-licensing deals. Please refer to our introductory report for more details and explanations.[…]
The third quarter of 2019 has been historical for European listed biotechs. The total amounts raised or secured by the 150+ listed companies under coverage reached 2168 mEUR, all categories included (equity issue, US IPO, warrants/equity lines, debt/non-dilutive sources). That makes this quarter likely the best ever… However, this number hides a much less positive[…]
31 abstracts, at least, should be presented at the coming ESMO 2019 meeting on therapies or products from European biotech companies in our universe. The meeting kicks off at the end of the week. Faron managed to get a Late-Breaking Abstract spot (Faron says it was accepted as a Poster Discussion), which is quite rare[…]
This is the fifth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2, Part 3 or Part 4. The full report is now available here. Part 5 – Table of Content 7. Deals 8. Portrait of a “typical” biotech company listed in Europe 9. Conclusion 2018[…]
This is the fourth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2 or Part 3. The full report is now available here. Part 4 – Table of Content 5. Financing 6. Other financial metrics: cash burn, extra cash sources, cash balance, profits & losses 6.1[…]
This is the third part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, or Part 2. The full report is now available here. Part 3 – Table of Content 3. Market data 3.1 Market capitalization 3.2 Stock performances 3.3 Market Liquidity 4. Employment References 3. Market data 3.1[…]
This is the second part of our 2018 review dedicated to the European public biotech landscape. Check out the introduction and first part here. The full report is now available here. Part 2 – Table of Content 2. R&D Pipeline & Commercial Products 2.1 Unique product candidates in active clinical development, indications and therapeutic areas[…]
This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data at the European level[…]
Dear all, this is my great pleasure to announce the launch of biotechradar.eu today. This is a subscription service for pro-investors and profressionals in Life Sciences, providing data and intel on the European landscape of public biotech companies. Pipeline data and financials are obviously the backbones of the service, but there’s indeed more. The underlying[…]
biotech radar UNIVERSE
Companies Covered (Core Coverage & Extra Coverage)
Deal Monitor – European Public Biotech Companies
Financing Monitor – European Public Biotech Companies
DATA & INTEL FOR A 360° View on the Public biotech Landscape in europe
How We Help Investors & Professionals in Life Sciences
DISCOVER NEW COMPANIES WITH OUR BROAD COVERAGE
Our data coverage is focused on the European biotech companies listed on the main stock exchange platforms in 12 countries: Germany, France, Belgium, Netherlands, Switzerland, UK, Spain, Italy and the Nordic countries. The coverage only includes biotech companies developping therapeutics, we DO NOT COVER: pharma companies, the medtech landscape, nor the associated service companies (CRO, CMO, Drug Discovery, etc…), with few exceptions nevertheless. We include some potentially high-growth companies in the field of diagnostics, as well as some specialty companies.
ACCESS INSIGHTS, GAIN TIME, SPOT OPPORTUNITIES
We provide timely detailed data on the pipeline of all the companies, representing more than 1200 programs currently at the clinical stage (more than 2000 programs overall). Our service is both a discovery tool for potential new opportunities, and a platform tracking any event from the covered companies. It may also be seen as a promoting support for this universe, even though we are completely independent. Maximize knowledge in a short period, and gain a tremendous amount of time in your due dilligence and research process. We do not cover the scientific analysis part (results from clinical trials).
FINANCIAL DATA, MARKET DATA, DEALS, FINANCINGS…
We provide up-to-date relevant financial data on the companies: cash positions, cash burn rates, live cash estimates, cash runways, income statements. Don’t get lost in the numerous financing schemes with our detailed tracking of the financing lines (as much as decently possible). Access our database of financing agreements back up to 2010 on many covered companies, parse our records of the various partenerships between the companies and third parties. Keep track of the stocks on our free dashboards (disclaimers apply), and more.
INDICATORS AND ANALYTICS (IN DEVELOPMENT)
We will strive to deliver specific insights on the public European biotech landscape by leveraging our large -and still growing- set of data. We aim to provide intelligence, highlighting dynamics, as well as identifying trends in various relevant areas. We will also provide a picture of the landscape periodically. Some analysis may be published in the form of reports, reserved to our clients or made public. We will also develop indicators thought to be specifically relevant for investors.
Biotech Radar Service
All in one place, for PROs only
European hub for investors and professionnals
in Life Sciences
Our Service covers 100% of the pipeline & financial data of the European public biotech companies.
For the broader set of data, the Service currently has 2 main levels of Coverage: the Core Coverage, with the most extended set including history, and the Extra Coverage, with a less extended set and only including the most recent records (complete list of companies below).
The Core Coverage includes more than 40% of the public European biotech companies to date (main European stock markets only), represents more than 60% of the active programs at the clinical stage, and weights more than 60% of the total market capitalization out of our whole Universe. More than 70% of turnovers are concentrated on companies from the Core Coverage.
The market data can be accessed for free.
Through our Service, we strive to bring value to our clients, also indirectly showcasing this segment of the Biotech landscape at the same time.
We DO NOT provide any recommendations on any financial instruments. We own our data and we collect them from corporate or well-trusted sources (e.g. clinicaltrials.gov). We operate as an independent company.
All the programs, all the product candidates & all the commercial products
All the main financial figures
on the Core Coverage
Active Clinical Programs & market capitalization
on the Core Coverage